Chronix Biomedical, U of Calgary to Co-Develop Commercial Blood Test for Mad Cow Disease | GenomeWeb

This story was originally published on April 13.

Chronix Biomedical said today that it is partnering with the University of Calgary to develop a commercial version of Chronix's serum DNA-based blood test for the early detection of bovine spongiform encephalopathy, also known as mad cow disease.

The BSE assay will be the first commercial application of Chronix's technology, which detects, amplifies, and sequences disease-specific circulating nucleic acids that are released into the bloodstream by damaged and dying cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.